E. Moore

发表

Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine

C. Salvatore, E. Moore, Eric L. Moore, 2012, British journal of pharmacology.

Pharmacological Properties of MK-3207, a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist

J. Vacca, C. Regan, Y. S. Tang, 2010, Journal of Pharmacology and Experimental Therapeutics.

Novel oxazolidinone calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraine.

H. Selnick, M. Fraley, D. Gauvreau, 2015, Bioorganic & medicinal chemistry letters.

Mapping the CGRP receptor ligand binding domain: tryptophan-84 of RAMP1 is critical for agonist and antagonist binding.

D. Hay, S. Kane, J. Gingell, 2010, Biochemical and biophysical research communications.

Examining the binding properties of MK-0974: a CGRP receptor antagonist for the acute treatment of migraine.

A. W. Shaw, Y. S. Tang, S. Kane, 2009, European journal of pharmacology.

Pharmacological Characterization of MK-0974 [N-[(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist for the Treatment of

A. W. Shaw, J. Vacca, Victor K. Johnston, 2008, Journal of Pharmacology and Experimental Therapeutics.

Active CGRP Receptor Antagonist for the Treatment of Migraine

A. W. Shaw, J. Vacca, S. Graham, 2007 .

Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor

E. Hostetler, C. Regan, M. Fraley, 2020, The Journal of Pharmacology and Experimental Therapeutics.

[(11)C]MK-4232: The First Positron Emission Tomography Tracer for the Calcitonin Gene-Related Peptide Receptor.

Sandra M. Sanabria-Bohórquez, L. Gantert, E. Hostetler, 2013, ACS medicinal chemistry letters.

MK-8825: a potent and selective CGRP receptor antagonist with good oral activity in rats.

J. Vacca, H. Selnick, S. Graham, 2012, Bioorganic & medicinal chemistry letters.

Novel CGRP receptor antagonists from central amide replacements causing a reversal of preferred chirality.

J. Vacca, H. Selnick, R. Bednar, 2010, Bioorganic & medicinal chemistry letters.

Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists.

Cory R. Theberge, J. Vacca, J. Hochman, 2006, Bioorganic & medicinal chemistry letters.

The discovery of highly potent CGRP receptor antagonists.

Cory R. Theberge, J. Vacca, Victor K. Johnston, 2009, Bioorganic & medicinal chemistry letters.

HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity

D. Henze, M. Urban, S. R. Eid, 2008, Molecular pain.

Structural Basis for Selectivity and Diversity in Angiotensin II Receptors

M. Rudd, R. Stevens, M. Hunter, 2017, Nature.

Novel CGRP receptor antagonists through a design strategy of target simplification with addition of molecular flexibility.

J. Vacca, H. Selnick, I. M. Bell, 2009, Bioorganic & medicinal chemistry letters.

Identification of potent, highly constrained CGRP receptor antagonists.

Steven S. Sharik, Cory R. Theberge, J. Vacca, 2010, Bioorganic & medicinal chemistry letters.

Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist.

J. Vacca, C. Regan, T. Prueksaritanont, 2010, ACS medicinal chemistry letters.

The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists.

Cory R. Theberge, J. Vacca, Victor K. Johnston, 2009, Bioorganic & medicinal chemistry letters.